Transcatheter Interventions Online 2022 - On Demand
Published: 09 March 2022
-
Views:
46266
-
Likes:
7
-
Views:
46266
-
Likes:
7
-
Up Next -
1h 2m 19sPart 1 | Session 2 Session 1.2: Live Cases and Discussion
-
45m 54s
-
59m 47sPart 1 | Session 4 Session 1.3: Practical Perspectives in the Context of TAVI
-
1h 2m 44sPart 1 | Session 5 Session 1.4: Live Cases and Discussions
-
44m 31sPart 1 | Session 6 BREAKOUT: Current Data and Future Direction in LAAC
-
48m 20s
-
1h 1m 36sPart 2 | Session 1 Session 2.1: Strategies for Calcified Coronary Lesions Anno 2022
-
57m 43sPart 2 | Session 2 Session 2.2: Live Cases and Discussion
-
45m 25s
-
1h 1m 32sPart 2 | Session 4 Session 2.3: Practical Pearls Towards a More Advanced CTO Programme
-
56m 37sPart 2 | Session 5 Session 2.4: Live Cases and Discussion
-
56m 12s
-
45m 31sPart 2 | Session 7 BREAKOUT: Coronary Physiology in STEMI patients today: Why? When? How?
-
1h 32sPart 3 | Session 1 Session 3.1 & 3.2: Keynote & Controversies
-
59m 54sPart 3 | Session 2 Session 3.3: Live Cases and Discussion
-
51m 53s
-
1h 3m 33sPart 3 | Session 4 Session 3.4: Debates
-
47m
Overview
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Day One: Structural Heart Disease
Part 2
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Part 3
Day Three: Debates and Controversies
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Kendra J Grubb
Surgical Director
Dr Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. She is also an associate professor of surgery at Emory University School of Medicine.
Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centred approach to the treatment of cardiovascular disease.
Her clinical interests include valve repair or replacement, coronary artery bypass graft surgery (CABG), transcatheter aortic valve replacement (TAVR) and hybrid coronary revascularization.
Dr Grubb research interests are innovative cardiac surgery technologies. She has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy and the GORE® conformable TAG® thoracic endoprosthesis for the primary treatment of…
Lars Søndergaard
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).
Azeem Latib
Section Head of Interventional Cardiology
Dr Mohamed Azeem Latib is a world-leading expert in Interventional Cardiology. Dr Latib is the Section Head and Director of Interventional Cardiology as well as the Director of Structural Heart Interventions at the Montefiore-Einstein Center for Heart and Vascular Care.
He is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).
His focus is on complex coronary interventions as well as transcatheter aortic, mitral and tricuspid interventions. His main clinical interests include Complex Coronary Interventions, Structural Heart Disease and New Device Innovation. He has extensive clinical experience in TAVR and MitraClip, as well as expertise in novel and new devices to treat mitral and tricuspid valve disease minimally invasively without open-heart surgery.
Dr Latib is currently involved in the development of the NeoChord NeXuS Transcatheter Mitral Chordal…
David Hildick-Smith
Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.
A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment.